Dual Agonism: Moving Beyond Glycemic Control with Incretins derived from symposia taped at the 58th EASD Annual Meeting and IDF World Diabetes Congress 2022
This activity is supported by an educational grant by Lilly.
Click Here to Manage Email Alerts
CE Activity Release Date: December 28, 2022
CE Activity Expiration Date: December 27, 2023
Time to Complete activity: 2.25 hours
DESCRIPTION
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.
What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes.
TARGET AUDIENCE
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Identify individuals with T2D who may benefit from earlier treatment intensification to achieve optimal glucose control and overall health in accordance with current guidelines
- Integrate practical considerations, experience, and SDM techniques to help individuals with T2D achieve and maintain weight loss for optimal outcomes
- Relate the pathophysiology of GLP-1 and GIP to the incretin effect and potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Interpret the clinical implications of the efficacy and safety data of novel dual agonists for T2D and their potential impact on the treatment paradigm
AGENDA
Chapter 1: Potential Benefits of Incretins Beyond Glycemic Control in T2D
- Addressing Unmet Needs in T2D
- Delineating the Incretin Effect and the Roles of GLP-1 and GIP
- Benefits of Agonism of Multiple Receptors: Mechanism of Action of Unimolecular Dual Agonists
- Clinical Implications of Dual Agonis Efficacy and Safety Data
- Case Studies Addressing Comorbidities, Treatment Intensification, and Shared Decision Making
- Ask Me Anything - Q&A with Faculty
Chapter 2: Demystifying the Evolving Science and Potential Role of Incretins in T2D
- Addressing Unmet Needs in T2D: Comorbidities, Treatment Intensification, Shared Decision Making for Weight Management
- Demystifying the Evolving Science Behind the Incretin Effect and the Roles of GLP-1 and GIP; Benefits of Agonism of Multiple Receptors that Affect Energy Homeostasis; Mechanism of Action of Unimolecular Dual Agonists
- Clinical Implications of Tirzepatide Efficacy and Safety Data; Identifying Ideal Candidates for Tirzepatide
- Ask Me Anything: Incretins Edition — Final Q&A with Faculty
- Concluding Comments and Key Points
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and Endocrine Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
SUPPORT STATEMENT
This activity is supported by an educational grant by Lilly.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc. and Endocrine Society are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Juan Pablo Frias, MD
Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, CA
Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: Akero, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, 89bio, Eli Lilly, Intercept, Ionis, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi
Advisory Board/Consultant: Akero, Altimmune, Axcella Health, Becton Dickinson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi
Speakers’ Bureau: Eli Lilly, Sanofi
Prof. Dr. med. Dr. h.c. Michael A. Nauck
Head of Clinical Research Diabetologie
St. Josef- Hospital Bochum Ruhr- University
Bochum, Germany
Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: AstraZeneca, Berlin-Chemie, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Novo Nordisk
Advisory Board/Consultant: Berlin-Chemie, Boehringer Ingelheim, Eli Lilly, Inventiva, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor Pharmaceutical, ShouTi (Gasherbrum)
Speakers’ Bureau: AstraZeneca, Berlin-Chemie, Eli Lilly, GlaxoSmithKline, Intas Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Sanofi, Sun Pharma
Bernhard Ludvik, MD
Associate Professor of Medicine
Head, 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Bernhard Ludvik, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Madrigal Pharmaceuticals, Novo Nordisk, Sanofi
Advisory Board/Consultant: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Speakers’ Bureau: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Stefano Del Prato, MD
Professor of Endocrinology
Chief – Section of Diabetes and Metabolic Diseases
Dept of Clinical and Experimental Medicine
University of Pisa
Pisa, Italy
Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: AstraZeneca, Boehringer Ingelheim
Advisory Board/Consultant: Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hengrui, Merck Sharp & Dohme, Novo Nordisk, Sandoz, Sanofi, Vertex
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, Sanofi
Thomas Forst, MD
Johannes Gutenberg University Mainz
Chief Medical Officer, Chairman of the Executive Board
Clinical Research Services
Mannheim, Germany
Thomas Forst, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AstraZeneca, Atrogi, Bayer, Cipla, Eli Lilly, EyeSense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, reMYND, Roche
Speakers’ Bureau: Amarin, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Cipla, Daiichi Sankyo, Eli Lilly, Fortbildungskolleg, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Santis
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Endocrine Society, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
